Benjamin Greiner, DO
Internal Medicine · Tulsa, OKNPI 1902428212
Payments from drug & device makers
Across 130 payments — averaging $27.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$1K
- AstraZeneca$441
- Novo Nordisk$352
- GSK$255
- Pfizer$234
- Boehringer Ingelheim$202
- plus $1K from 20 others
What the payments were for
- Grants$1,00028%
- Food & beverage$2,56972%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 1 | $1,000 |
| AstraZeneca | 18 | $441 |
| Novo Nordisk | 19 | $352 |
| GSK | 17 | $255 |
| Pfizer | 12 | $234 |
| Boehringer Ingelheim | 5 | $202 |
| Astellas Pharma US Inc | 6 | $135 |
| Lilly USA, LLC | 7 | $133 |
| Bayer | 7 | $119 |
| Eisai Inc. | 3 | $75 |
| Amgen | 5 | $73 |
| Daiichi Sankyo Inc. | 3 | $62 |
| Sumitomo Pharma America, Inc. | 3 | $58 |
| Exact Sciences | 4 | $57 |
| Phathom Pharmaceuticals, Inc. | 3 | $54 |
| Abbott | 3 | $53 |
| AbbVie | 2 | $41 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Dexcom, Inc. | 2 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Inspire Medical Systems, Inc. | 1 | $26 |
| Merck | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Gilead | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$3,569 in reported general payments places this provider in the 80th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 166 | $140,907 |
| JardianceEmpagliflozin | 107 | $124,249 |
| OzempicSemaglutide | 121 | $120,513 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 128 | $87,806 |
| MounjaroTirzepatide | 49 | $63,237 |
| XareltoRivaroxaban | 40 | $37,488 |
| JanuviaSitagliptin Phosphate | 24 | $30,273 |
| EntrestoSacubitril/Valsartan | 19 | $23,646 |
| RybelsusSemaglutide | 23 | $23,219 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $20,911 |
| TrulicityDulaglutide | 16 | $18,668 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $16,357 |
| Telmisartan | 284 | $13,694 |
| GemtesaVibegron | 20 | $12,968 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $12,423 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $352 | $143,732144 claims |
| PfizerEliquis | $234 | $140,907166 claims |
| Boehringer IngelheimJardiance | $202 | $124,249107 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $255 | $92,064146 claims |
| Lilly USA, LLCMounjaro, Trulicity | $133 | $81,90565 claims |
| MerckJanuvia | $19 | $30,27324 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $58 | $12,96820 claims |
| Astellas Pharma US IncMyrbetriq | $135 | $8,17515 claims |
| AstraZenecaBreztri Aerosphere | $441 | $6,42812 claims |
| AbbVieSynthroid | $41 | $2,73138 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Tulsa
- Al-Ola AbdallahTulsa$10.1M
- Melita TateTulsa$9.1M
- Renae MayerTulsa$766K
- Mousumi SomTulsa$391K
- Jesse RichardsTulsa$279K
- Madhuri LadTulsa$195K
- Lam leTulsa$191K
- Stacy ChronisterTulsa$163K
- Katherine CookTulsa$41K
- Layth Al AttarTulsa$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.